New Concepts for Animal Model Reflecting Heart Failure With Preserved Ejection Fraction (HFpEF)

Request Number REQ7352105
Due Date November 10, 2017
Request for Proposal Details
Additional Points of Contact
RFP Title
New Concepts for Animal Model Reflecting Heart Failure With Preserved Ejection Fraction (HFpEF)
RFP Description

NineSigma, representing a large European pharmaceutical company, invites proposals for concepts for animal models that reflect some of the key parameters of human HFpEF and could be used to test drug substances with the potential to improve HFpEF.


Heart failure with preserved ejection fraction (HFpEF) is a form of congestive heart failure. HFpEF is characterized by abnormality in diastolic function, the filling of the heart with blood between muscle contractions. In HFpEF the left ventricle of the heart exhibits increased stiffness and a reduced ability to relax and fill with blood. As a consequence less blood enters the left ventricle and, when the ventricle contracts, the volume of blood expelled is reduced. Cardiac output is decreased and blood does not circulate efficiently. Patients with HFpEF can experience breathlessness (especially during exercise and when lying down), fatigue, swelling of the legs and feet, and increased venous blood pressure.


The frequency of HFpEF is increasing due to the increasingly aging population, and greater incidence of diabetes and obesity. There is a high medical need for effective HFpEF treatments but there are no approved medications for this condition.


Our client wants to identify drugs to treat HFpEF, but research in HFpEF lacks relevant animal models that accurately recapitulate the complexities of the human disease and can be used to test potential drug candidates.


Key Success Criteria

  1. An animal model reflecting the human HFpEF situation:
  • A concept for an animal model


  • A partly developed model


  • An unvalidated model


  1. The model will reflect the key parameters of HFpEF. For example the model could reflect:
  • Changes in histopathological findings (fibrosis, concentric hypertrophy, capillary density)
  • Invasive hemodynamic changes (LVEDP, TAU, PV-loop analysis [EDPVR])
  • Biomarker (BNP, Nt-pro BNP)
  • Echocardiography marker (e.g. global longitudinal strain) or other imaging technologies
  • Changes in cardiac reserve
  • Alteration in macro- and microvascular function, pulmonary physiology, immune regulation, oxygen utilization, renal function, or skeletal muscle function
  • The ideal model would be based on comorbidities (e.g. diabetes, metabolic syndrome or chronic kidney disease)


  1. An in vivo animal model:
  • Established in an animal species, ideally large animals (dog, pig) but other animal species are acceptable
  • Can be used to test drug substances for their potential to improve HFpEF


Possible Approaches

Open to all approaches that meet the described requirements. 


Approaches not of interest



Preferred Collaboration types
Items to be submitted

Submitting a response:

  • Click the Response button at the top or bottom of the page
  • Log in, or register for Ninesights (you will be prompted)
  • Complete the simple response form
  • Attach additional files of information if you want to
  • Click Submit


Appropriate responses will include only non-confidential information:

  • Description of proposed solution
  • Status of technology and obstacles to be overcome (if required)
  • Brief overview of the respondent(s)
  • Overview of respondent(s) organization(s)
  • A description of your / your organisations experience with congestive heart failure and animals models of congestive heart failure
  • Please provide a list of any patent rights that you own, or have rights under, which cover your technology or animal model 

Area of Interest
Request Priority
This page does not have file attachments.
This page does not have file attachments.